Market Overview

UPDATE: J.P. Morgan Lowers PT on PDL BioPharma on Model Update

Related PDLI
US Stock Futures Mostly Flat Ahead Of Housing Data
PDL BioPharma Announces Successful Conclusion Of Debt Financing Agreement With Durata Therapeutics

In a report published Wednesday, J.P. Morgan reiterated its Neutral rating on PDL BioPharma (NASDAQ: PDLI) but lowered its price target from $7.00 to $6.00.

J.P. Morgan noted, “PDL BioPharma reported 4Q12 GAAP EPS of $0.34, which was 2 cents ahead of expectations (JPMe and cons: $0.32). Total revenues of $86M were in line with prior guidance. On the call, PDL noted a continued focus on adding additional revenue generating assets in 2013 and expect to exceed that invested last year. Indeed, progress was made in 2012 with three transactions ($125M total investment), but more are need to ensure sustainability post approaching Queen et. al. patent expiration. PDL reiterated its intention to evaluate the business in late 2013/2014 to determine whether to wind up the business. We are maintaining our cautious outlook on new royalty opportunities and maintaining a Neutral rating.”

PDL BioPharma closed on Tuesday at $6.98.

Latest Ratings for PDLI

DateFirmActionFromTo
May 2013Piper JaffrayInitiates Coverage onNeutral
Mar 2013JP MorganMaintainsNeutral
Jan 2013Credit SuisseDowngradesNeutralUnderperform

View More Analyst Ratings for PDLI
View the Latest Analyst Ratings

Posted-In: J.P. MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (PDLI)

Around the Web, We're Loving...

Get Benzinga's Newsletters